The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

You are here: Home / Archives for Antibody engineering

The James S. Huston Antibody Science Talent Award Competition is open!

by

The Huston Award is given by The Antibody Society to recognize and encourage upcoming scientists in the field of antibody engineering and therapeutics. Early-career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past 10 years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a live webinar on their work, which will also be made available on demand on The Antibody Society’s Learning Center and YouTube channel, and to give a lecture at the Antibody Engineering & Therapeutics conference.

The Award includes:

  • International recognition of the scientist’s accomplishments,
  • $1500 USD, and
  • Travel expenses and registration fee to attend the Antibody Engineering & Therapeutics conference, to be held December 14-16, 2023 in San Diego, California.

The award criteria and application details are here. Please note: Applicants must be nominated by a Member of the The Antibody Society.

What is it like to win? Our 2022 Huston Award recipient, Prof. Brandon DeKosky, describes his experience in this 2-min video.

Computational Antibody Discovery: State of the Art

by

Join us on June 22 for this free virtual Symposium – Registration is open!

Recent advances in computational and machine learning sciences have had a substantial impact on the antibody discovery process. Novel protocols that incorporate computational approaches can now be used to generate functional antibody therapeutics with good developability. In silico methods complement existing experimental strategies, and their use has become more mainstream in the biopharmaceutical industry. However, the application of computational de novo design strategies requires a thorough understanding of their capabilities, limitations, and experimental validation, as well as their place in the overall discovery pipeline and value chain.

In this Symposium, leading experts in computational antibody discovery from academia and industry will discuss their scientific strategies and progress to date. The event aims to provide a platform for better understanding of the breakthroughs and future directions in this multidisciplinary field, through talks, a panel session, and your questions and insights.

The Symposium commences at 8am PT/11am ET/4pm BST/5pm CET with speakers Drs. Pietro Sormanni, Yanay Ofran, Victor Greiff, Sandeep Kumar, and Ben Holland. The panel session, moderated by Konrad Krawczyk and including Jiye Shi, Tom Diethe and several speakers, will start at ~2pm ET. The Symposium concludes at 3pm ET following final remarks by Andrew Buchanan.

The full agenda is available here.

Biographical information for the Symposium speakers, panelists and hosts can be found here.

Register here for this free Symposium.

The Huston Antibody Science Talent Award competition is open!

by

The James S. Huston Antibody Science Talent Award is sponsored by The Antibody Society to recognize and encourage upcoming scientists in the field of Antibody Engineering and Therapeutics. Early career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past ten (10) years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a lecture on their work, which will be made available on-line on The Antibody Society’s website, and to give a lecture at the Antibody Engineering & Therapeutics conference in December 2022.

The award includes: international recognition of the scientist’s accomplishments, a $1500 USD prize, and travel costs and registration fees to attend the annual Antibody Engineering & Therapeutics conference in San Diego, California.

The nomination process details are here. The deadline for submission is September 15, 2022.

The Society has selected mAbs as its Official Journal!

by

The Antibody Society is pleased to announce that it has partnered with Taylor & Francis, a leading research publisher, to make mAbs the Society’s Official Journal. mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.

Since 2009, mAbs has published high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:

  • Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific antibodies, and single-domain antibodies
  • Machine learning and artificial intelligence applications
  • Non-clinical studies of antibodies, such as mechanism of action studies, safety, and efficacy studies in animals
  • Manufacturing and formulation
  • Regulatory review of antibody therapeutics
  • Post-approval topics, such as markets

The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year. Articles in the current volume (14) can be found here.

Members of The Antibody Society receive a 10% discount on article publication charges using their member code.

We look forward to a productive partnership with Taylor & Francis.

Join us on April 28th for our webinar on Fc silencing techniques!

by

Registration is open!

Thursday April 28, 2022, 11am ET

Speaker: Ian Wilkinson, PhD

Antibodies are nature’s pro-drugs, wonderfully evolved to target pathogens and activate immune systems. For certain indications where ADCC or CDC are required this is ideal, but for many other applications activation of inflammatory responses is unnecessary and potentially highly undesirable. In these situations silenced antibodies with either naturally low effector function or engineered Fc domains are the preferred option. However, many of the commonly used options in the clinic, such as IgG4, LALA or aglycosylation, are widely reported to still have residual Fc receptor binding and cytokine activation in patients.

This presentation will describe the first thorough comparison of most of the generic and proprietary Fc silencing mutations, demonstrating that all previously reported variants show residual binding to Fc receptors. It will also describe the discovery of a novel set of mutations, known as STR, that show no detectable binding to Fcγ receptors and do not elicit inflammatory cytokine responses. Meanwhile, immunogenicity, stability and PK are unaffected. This totally silenced variant has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.